Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313(2):165–173

Article  CAS  PubMed  Google Scholar 

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P et al (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846

Article  PubMed  PubMed Central  Google Scholar 

Gomis RR, Gawrzak S (2017) Tumor cell dormancy. Mol Oncol 11(1):62–78

Article  PubMed  PubMed Central  Google Scholar 

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2022) Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 23(3):382–392

Article  Google Scholar 

Foldi J, O’Meara T, Marczyk M, Sanft T, Silber A, Pusztai L (2019) Defining risk of late recurrence in early-stage estrogen receptor-positive breast cancer: clinical versus molecular tools. J Clin Oncol 37(16):1365–1369

Article  CAS  PubMed  Google Scholar 

Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM et al (2020) Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 38(34):3987–3998

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M et al (2021) Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 22(2):212–222

Article  CAS  PubMed  Google Scholar 

Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB et al (2021) Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the Penelope-B trial. J Clin Oncol 39(14):1518–1530

Article  CAS  PubMed  Google Scholar 

Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D et al (2024) Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med 390(12):1080–1091

Article  CAS  PubMed  Google Scholar 

Rastogi P, O’Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS et al (2024) Adjuvant abemaciclib plus endocrine therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol 42(9):987–993

Article  CAS  PubMed  PubMed Central  Google Scholar 

Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M et al (2023) Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol 15:17588359231178124

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fasching PA, Stroyakovskiy D, Yardley D, Huang CS, Crown JP, Bardia A et al (2024) LBA13 adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Ann Oncol 35:S1207

Article  Google Scholar 

Burris HA, Chan A, Bardia A, Thaddeus Beck J, Sohn J, Neven P et al (2021) Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. Br J Cancer 125(5):679–686

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM et al (2021) Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist 26(1):e53–e65

Article  CAS  PubMed  Google Scholar 

Barrios CH, Harbeck N, Hortobagyi GN, O’Shaughnessy J, Huang CS, Jimenez MM et al (2024) 113MO NATALEE update: safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC). ESMO Open 9:103101

Article  Google Scholar 

Rugo HS, O’Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I et al (2022) Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol 33(6):616–627

Article  CAS  PubMed  Google Scholar 

Johnston SRD, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P et al (2023) Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 24(1):77–90

Article  CAS  PubMed  Google Scholar 

Beusterien K, Maculaitis MC, Hallissey B, Gaschler MM, Smith ML, Law EH (2021) Patient, oncologist, and payer preferences for adjuvant endocrine therapy and CDK4/6 inhibitor regimens in early-stage breast cancer: a discrete choice experiment. Patient Prefer Adherence 15:611–623

Article  PubMed  PubMed Central  Google Scholar 

Omori Y, Enatsu S, Cai Z, Ishiguro H (2019) Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan. Breast Cancer 26(5):652–662

Article  PubMed  Google Scholar 

Maculaitis MC, Liu X, Will O, Hanson M, McRoy L, Berk A, Crastnopol M (2020) Oncologist and patient preferences for attributes of CDK4/6 inhibitor regimens for the treatment of advanced/metastatic HR positive/HER2 negative breast cancer: discrete choice experiment and best-worst scaling. Patient Prefer Adherence 14:2201–2214

Article  PubMed  PubMed Central  Google Scholar 

Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM (2019) Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics 37(2):201–226

Article  PubMed  Google Scholar 

Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA et al (2011) Conjoint analysis applications in health–a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 14(4):403–413

Article  PubMed  Google Scholar 

Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA et al (2013) Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health 16(1):3–13

Article  CAS  PubMed  Google Scholar 

Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR (2010) Conjoint analysis applications in health—how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient 3(4):249–256

Article  PubMed  Google Scholar 

Ryan M, Gerard K (2003) Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy 2(1):55–64

PubMed  Google Scholar 

Hortobagyi G, Stroyakovsky D, Yardley D, Huang C-S, Fasching PA, Crown J et al (2024) Abstract GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial. Cancer Res 84:GS03-03

Article  Google Scholar 

Kisqali® [Prescribing Information] (2022) East Hanover: Novartis Pharmaceuticals Corporation. https://www.novartis.us/sites/www.novartis.us/files/kisqali.pdf

Verzenio® [Prescribing Information] (2023) Indianapolis: Eli Lilly and Company

Ryan M (2004) Discrete choice experiments in health care. BMJ 328(7436):360–361

Article  PubMed  PubMed Central  Google Scholar 

Cardoso F, Rihani J, Aubel D, de Courcy J, Harmer V, Harbeck N et al (2022) 178P Assessment of side effects (SEs) impacting quality of life (QoL) in patients (pts) undergoing treatment (tx) for advanced breast cancer (ABC) in clinical practice: a real-world (RW) multi-country survey. Ann Oncol 33:S208–S209

Article  Google Scholar